ANI Pharmaceuticals, Inc. (BST:BSFA)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.44B +26.5% |
| Revenue (ttm) | 801.13M +37.0% |
| Net Income | 72.80M |
| EPS | 3.38 |
| Shares Out | n/a |
| PE Ratio | 19.84 |
| Forward PE | 8.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 68.50 |
| Previous Close | 69.00 |
| Day's Range | 68.00 - 69.00 |
| 52-Week Range | 54.50 - 84.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, gr... [Read more]
News
ANI Pharmaceuticals initiated with a Hold at Canaccord
Canaccord analyst Gary Nachman last night initiated coverage of ANI Pharmaceuticals (ANIP) with a Hold rating and $91 price target While ANI’s valuation looks attractive, the stock setup “is a…
ANI Pharmaceuticals intends to appeal rulings in CG Oncology matter
ANI Pharmaceuticals (ANIP) announced that Judge Sheldon K. Rennie, on July 16, denied ANI’s post-trial motions for a new trial and judgment as a matter of law. ANI intends to…
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI's post-trial...
ANI Pharmaceuticals initiated with a Hold at Canaccord
Canaccord initiated coverage of ANI Pharmaceuticals (ANIP) with a Hold rating and $91 price target
ANI Pharmaceuticals reports ‘positive’ results from Phase 4 Synchronicity trial
ANI Pharmaceuticals (ANIP) announced positive topline data from its Phase 4, open-label, single-arm Synchronicity clinical trial of Fluocinolone Acetonide Intravitreal Implant in patients with chronic...
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis
PRINCETON, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced positive topline data from its Phase 4, open-label, single-arm SYNCHRON...
ANI Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
Management outlined a strategy focused on rare disease growth, with Cortrophin Gel and ILUVIEN as key assets and a major sales force expansion targeting under-penetrated markets. Strong momentum is expected to drive a significant second-half sales ramp, while a new licensing deal adds royalty potential.
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
PRINCETON, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fire...
ANI Pharmaceuticals Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and stock plan approval. All proposals passed, including annual advisory votes on compensation. No shareholder questions were raised during the session.
ANI Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 20% revenue growth and 24% adjusted EBITDA growth, driven by Rare Disease and Generics, with Cortrophin Gel revenues up 42% year-over-year. 2026 guidance was raised, and a $100M share repurchase program was announced.
ANI Pharmaceuticals Earnings release: Q1 2026
ANI Pharmaceuticals released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
ANI Pharmaceuticals Quarterly report: Q1 2026
ANI Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 8, 2026.
ANI Pharmaceuticals Slides: Q1 2026
ANI Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 8, 2026.
ANI Pharmaceuticals reports Q1 non-GAAP EPS $2.05, consensus $1.30
Reports Q1 revenue $237.46M, consensus $207.63M. “We delivered a strong first quarter, generating $237.5M in revenue and $63.0M in adjusted non-GAAP EBITDA, with solid performance across all business ...
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
PRINCETON, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended Ma...
ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET
PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its first quarter 2026 financial results...
ANI Pharmaceuticals announces FDA approval, launch of Pimozide Tablets
ANI Pharmaceuticals (ANIP) announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI’s Pimozide Tablets is the generic version of the reference listed drug Orap. U.S. annual sales…
ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI's Pimozide Tablets i...
ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules
PRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg ...
ANI Pharmaceuticals Proxy statement: Proxy filing
ANI Pharmaceuticals filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
ANI Pharmaceuticals Proxy statement: Proxy filing
ANI Pharmaceuticals filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
ANI Pharmaceuticals launches Isosorbide Mononitrate Tablet USP
ANI Pharmaceuticals (ANIP) announced that following final approval from the FDA for its Abbreviated New Drug Application, or ANDA, the Company launched Isosorbide Mononitrate Tablet USP, 10 mg and 20…
ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet
PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administrati...
ANI Pharmaceuticals announces publication of iluvien clinical trial results
ANI Pharmaceuticals (ANIP) announced publication of the results from the NEW DAY clinical trial involving iluvien – fluocinolone acetonide intravitreal implant -, 0.19 mg for use in appropriate patien...